Table 1.

Description of parameters used in the simulation study.^17,26,32

Symbol (unit)	Description	Peptide	Affibody	Antibody
$A$ (unitless)	Distribution fraction	0.02	0.6	0.4
$\alpha$ (${\min }^{-1}$)	Distribution phase constant	0.3	0.2	0.03
$B$ (unitless)	Elimination fraction	2E-03	0.4	0.5
$\beta$ (${\min }^{-1}$)	Elimination phase constant	6E-04	5E-03	3E-04
Tumor $K_1$a (${\min }^{-1}$)	Extravasation rate from plasma to tumor tissue	$0.4\pm 0.2$	$0.01\pm 0.04$	2E-04
Tumor $k_2$a (${\min }^{-1}$)	Efflux rate from tumor tissue to plasma	$0.2\pm 0.2$	$0.3\pm 0.6$	8E-03
Normal $K_1$a (${\min }^{-1}$)	Extravasation rate from plasma to normal tissue	$0.1\pm 0.03$	$0.01\pm 0.02$	2E-04
Normal $k_2$a (${\min }^{-1}$)	Efflux rate from normal tissue to plasma	$0.02\pm 0.01$	$0.3\pm 0.2$	8E-03
$k_{\text{on}}$ (${\mathrm{nM}}^{-1}.{\min }^{-1}$)	Binding rate	0.1	0.04	0.16
$k_{\text{off}}$ (${\min }^{-1}$)	Dissociation rate	0.1	0.1	0.07
$K_D$ (nM)	Equilibrium dissociation rate constant	1	3	0.4

^aFor peptide and affibody groups, these values are estimated from the experimental part of this study for U251 tumors. For antibody group, the average values are taken from the references. Data show within group variance.